If the treatment works, do we need to know why?: The promise of immunotherapy for experimental medicine

Journal of Experimental Medicine

Volumn 204, Issue 10, 2007, Pages 2249-2252

  Ehrenstein, Michael R ^a   Mauri, Claudia ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR;

ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; DISEASE SEVERITY; DRUG MECHANISM; EXPERIMENTAL MEDICINE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANIMALS; DISEASE; HUMANS; IMMUNOTHERAPY; PHARMACEUTICAL PREPARATIONS;

EID: 34948836136     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20071737     Document Type: Review

References (32)

1. Rhen, T., and J.A. Cidlowski. 2005. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N. Engl. J. Med. 353:1711-1723.
2. Brown, S.J., and M.T. Abreu. 2005. Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease. Curr. Opin. Drug Discov. Devel. 8:160-168.
3. Sandborn, W.J., S.B. Hanauer, S. Katz, M. Safdi, D.G. Wolf, R.D. Baerg, W.J. Tremaine, T. Johnson, N.N. Diehl, and A.R. Zinsmeister. 2001. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 121:1088-1094.
4. Van den Brande, J.M., H. Braat, G.R. van den Brink, H.H. Versteeg, C.A. Bauer, I. Hoedemaeker, C. van Montfrans, D.W. Hommes, M.P. Peppelenbosch, and S.J. van Deventer. 2003. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 124:1774-1785.
5. Mitoma, H., T. Horiuchi, N. Hatta, H. Tsukamoto, S. Harashima, Y. Kikuchi, J. Otsuka, S. Okamura, S. Fujita, and M. Harada. 2005. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology. 128:376-392.
6. van Vollenhoven, R., A. Harju, S. Brannemark, and L. Klareskog. 2003. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann. Rheum. Dis. 62:1195-1198.
7. Hyrich, K.L., M. Lunt, K.D. Watson, D.P. Symmons, and A.J. Silman. 2006. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 56:13-20.
8. Nadkarni, S., C. Mauri, and M.R. Ehrenstein. 2007. Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J. Exp. Med. 204:33-39.
9. Svensson, L., J. Jirholt, R. Holmdahl, and L. Jansson. 1998. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin. Exp. Immunol. 111:521-526.
10. Williams, R.O., M. Feldmann, and R.N. Maini. 1992. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA. 89:9784-9788.
11. Mori, L., S. Iselin, G. De Libero, and W. Lesslauer. 1996. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J. Immunol. 157:3178-3182.
12. Campbell, I.K., K. O'Donnell, K.E. Lawlor, and I.P. Wicks. 2001. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J. Clin. Invest. 107:1519-1527.
13. Feldmann, M., and R.N. Maini. 2003. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 9:1245-1250.
14. Kouskoff, V., A.S. Korganow, V. Duchatelle, C. Degott, C. Benoist, and D. Mathis. 1996. Organ-specific disease provoked by systemic autoimmunity. Cell. 87:811-822.
15. Yanaba, K., Y. Hamaguchi, G.M. Venturi, D.A. Steeber, E.W. St Clair, and T.F. Tedder. 2007. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J. Immunol. 179:1369-1380.
16. Ruddle, N.H., C.M. Bergman, K.M. McGrath, E.G. Lingenheld, M.L. Grunnet, S.J. Padula, and R.B. Clark. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1193-1200.
17. Selmaj, K., C.S. Raine, and A.H. Cross. 1991. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 30:694-700.
18. Korner, H., D.S. Riminton, D.H. Strickland, F.A. Lemckert, J.D. Pollard, and J.D. Sedgwick. 1997. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J. Exp. Med. 186:1585-1590.
19. Owens, T., H. Wekerle, and J. Antel. 2001. Genetic models for CNS inflammation. Nat. Med. 7:161-166.
20. 1999. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 53:457-465.
21. Wolf, S.D., B.N. Dittel, F. Hardardottir, and C.A. Janeway Jr. 1996. Experimental auto-immune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 184:2271-2278.
22. Fillatreau, S., C.H. Sweenie, M.J. McGeachy, D. Gray, and S.M. Anderton. 2002. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3:944-950.
23. Lyons, J.A., M. San, M.P. Happ, and A.H. Cross. 1999. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur. J. Immunol. 29:3432-3439.
24. Antel, J., and A. Bar-Or. 2006. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J. Neuroimmunol. 180:3-8.
25. Winthrop, K.L. 2006. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat. Clin. Pract. Rheumatol. 2:602-610.
26. Winkelstein, J.A., M.C. Marino, H.M. Lederman, S.M. Jones, K. Sullivan, A.W. Burks, M.E. Conley, C. Cunningham-Rundles, and H.D. Ochs. 2006. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore). 85:193-202.
27. Popa, C., M.J. Leandro, G. Cambridge, and J.C. Edwards. 2007. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford). 46:626-630.
28. Paroli, M., D. Accapezzato, V. Francavilla, A. Insalaco, A. Plebani, F. Balsano, and V. Barnaba. 2002. Long-lasting memory-resting and memory-eff ector CD4+ T cells in human X-linked agammaglobulinemia. Blood. 99:2131-2137.
29. Neelapu, S.S., L.W. Kwak, C.B. Kobrin, C.W. Reynolds, J.E. Janik, K. Dunleavy, T. White, L. Harvey, R. Pennington, M. Stetler-Stevenson, et al. 2005. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat. Med. 11:986-991.
30. Hafler, D. 2007. Cytokines and interventional immunology. Nat. Rev. Immunol. 7:423.
31. Chatenoud, L. 2005. CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications. Curr. Opin. Immunol. 17:632-637.
32. Marks, D.J., M.W. Harbord, R. MacAllister, F.Z. Rahman, J. Young, B. Al-Lazikani, W. Lees, M. Novelli, S. Bloom, and A.W. Segal. 2006. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet. 367:668-678.